In a report released today, Balaji Prasad from Barclays maintained a Buy rating on Teva Pharmaceutical (TEVA – Research Report), with a price ...

Detailed results presented at a medical congress help reinforce analyst expectations the drug, called duvakitug, will be ...

Teva and Sanofi's duvakitug showed promising results in a Phase 2b study for ulcerative colitis and Crohn's disease, with ...

Sanofi has shared a deeper dive into its 469 million euro ($491 million) bowel disease bet, publishing phase 2 data that ...

Teva Pharmaceuticals and Alvotech have announced the US launch of the Selarsdi (ustekinumab-aekn) injection, a biosimilar to ...

Teva Pharmaceutical Industries and partner Alvotech said the Food and Drug Administration agreed to review their AVTO6 ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Investors with a lot of money to spend have taken a bearish stance on Teva Pharmaceutical Indus (NYSE:TEVA). And retail traders should know. We noticed this today when the trades showed up on ...

Axsome Therapeutics shares were up 14% in premarket trading after reaching a settlement with Teva Pharmaceuticals. Shares were trading around $120.01. The stock is up 8.3% over the last year.

Looking ahead, revenue is forecast to grow 3.6% p.a. on average during the next 3 years, compared to a 8.6% growth forecast for the Pharmaceuticals industry in the US.

Teva Pharmaceutical (NYSE:TEVA) shares snapped six straight sessions of losses, as the stock closed 0.88% higher at $17.21 on Wednesday. The company lost over 20% in the preceding six sessions.